ForPatients
by Roche

Triple Negative Breast Cancer

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Trial Status	Trial Runs In	Trial Identifier
Completed	24 Countries	NCT03125902 2016-004024-29 MO39196

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 [PD-L1] antibody) administered in combination with paclitaxel compared with placebo in combination with paclitaxel in participants with previously untreated, inoperable locally advanced or metastatic, centrally confirmed TNBC. Participants will be randomized in a 2:1 ratio to receive atezolizumab or placebo plus paclitaxel until disease progression or unacceptable toxicity or end of study, whichever occurs first (maximum up to approximately 40 months). In addition, the Sponsor may decide to terminate the study at any time.

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT03125902 2016-004024-29 MO39196
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years	No

© 2022 F. Hoffmann-La Roche Ltd